PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20036131-2 2010 Lobeline (1) is a potent antagonist at alpha4beta2 * nicotinic acetylcholine receptors, has moderate affinity (K(i)=5.46microM) for VMAT2, and is being investigated currently as a clinical candidate for treatment of psychostimulant abuse. Lobeline 0-8 solute carrier family 18 member A2 Rattus norvegicus 132-137 29427069-3 2018 VMAT2 inhibition by the natural product, lobeline, reduced methamphetamine-evoked dopamine release, methamphetamine-induced hyperlocomotion, and methamphetamine self-administration in rats. Lobeline 41-49 solute carrier family 18 member A2 Rattus norvegicus 0-5 24484975-4 2014 Lobeline, the major alkaloid in Lobelia inflata, potently inhibited VMAT2, methamphetamine-evoked striatal dopamine release, and methamphetamine self-administration in rats but exhibited high affinity for nicotinic acetylcholine receptors (nAChRs). Lobeline 0-8 solute carrier family 18 member A2 Rattus norvegicus 68-73 23875705-0 2013 Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivo. Lobeline 28-36 solute carrier family 18 member A2 Rattus norvegicus 11-16 20036131-10 2010 Thus, esterification of the lobeline molecule may be a useful structural modification for the development of lobeline analogs with improved selectivity at VMAT2. Lobeline 28-36 solute carrier family 18 member A2 Rattus norvegicus 155-160 20036131-10 2010 Thus, esterification of the lobeline molecule may be a useful structural modification for the development of lobeline analogs with improved selectivity at VMAT2. Lobeline 109-117 solute carrier family 18 member A2 Rattus norvegicus 155-160 11841781-11 2002 The development of lobeline and lobeline analogs with targeted selectivity at VMAT2 represents a novel class of therapeutic agents having good potential as efficacious treatments for methamphetamine abuse. Lobeline 32-40 solute carrier family 18 member A2 Rattus norvegicus 78-83 15331654-8 2005 The maintenance of hyperthermia during lobeline + METH exposure restored the effects of METH on decreases in VMAT-2 as well as dopamine and 5-HT content. Lobeline 39-47 solute carrier family 18 member A2 Rattus norvegicus 109-115 11841781-5 2002 Reevaluation of the mechanism by which lobeline alters dopamine function reveals that its primary mechanism is inhibition of dopamine uptake and promotion of dopamine release from the storage vesicles within the presynaptic terminal, via an interaction with the tetrabenazine-binding site on the vesicular monoamine transporter (VMAT2). Lobeline 39-47 solute carrier family 18 member A2 Rattus norvegicus 329-334 11841781-11 2002 The development of lobeline and lobeline analogs with targeted selectivity at VMAT2 represents a novel class of therapeutic agents having good potential as efficacious treatments for methamphetamine abuse. Lobeline 19-27 solute carrier family 18 member A2 Rattus norvegicus 78-83 9648873-7 1998 These results suggest that lobeline specifically interacts with DTBZ sites on VMAT2 to inhibit DA uptake into synaptic vesicles. Lobeline 27-35 solute carrier family 18 member A2 Rattus norvegicus 78-83